

### Official launch event of the JPIAMR Strategic Research Agenda

"THE MICROBIAL CHALLENGE

- AN EMERGING THREAT

TO HUMAN HEALTH"

# **Towards a Global Research Agenda for AMR**

03 April 2014

De Warande, Zinnerstraat 1, Brussels, Belgium

# **Objectives**

- To achieve wide recognition and awareness for the findings and roadmap of the SRA
- To encourage uptake of the recommendations developed in the SRA by a wide range of stakeholders
- To encourage a follow-up and future collaboration between research funding agencies in the field of AMR
- To encourage the participation of private funders
- To discuss among international partner funders of key priorities of the SRA and what is relevant for them by developing global funding opportunities
- To work towards a global JPI

#### **A**GENDA

| Opening session                             |       |   |  |  |  |
|---|-------|---|--|--|--|
| Moderator /introducer: Fulvio Esposito, GPC |       |   |  |  |  |
| 15'   | 9:30  | Welcome Address by a representative from Ministry of Health and Social Affairs, Sweden                      |  |  |  |
| 20'   | 9:45  | Welcome Address by <i>Máire Geoghegan-Quinn, European Commissioner for</i> Research, Innovation and Science |  |  |  |
| 20'   | 10:10 | Why is AMR a human threat? By <i>Carmen Pessoa,</i> Head of the AMR unit, World Health Organisation         |  |  |  |
| 20′   | 10.30 | Why a Joint Programming Initiative on AMR? By <i>Mats Ulfendahl, MB Chair</i> , Swedish Research Council    |  |  |  |

| 30' | 10:50 | COFFEE BREAK |
|-----|-------|--------------|
|     |       |              |

# SRA Presentation session: The JPIAMR Strategic Research Agenda

# Moderator: a representative from the German Ministry

| 25' | 11:20       | The JPIAMR Strategic Research Agenda by <i>Herman Goossens, SAB Chair,</i> University of Antwerp                                     |
|-----|-------------|--|
| 25' | 11:45       | Reflections on the SRA from policy point of view by <b>John Watson,</b> Deputy Chief Medical Officer at the Department of Health, UK |
| 25' | 12:10       | Reflections on the SRA from the industry point of view by <b>Richard Bergström,</b> Director, <i>EPFIA</i>                           |
| 30' | 12:35       | Open discussion  |
| 60' | LUNCH BREAK |  |

# **Session 1: Funding of AMR programmes**

Moderator: a representative from INSERM (tbc)

#### Scope:

- Presentation mapping analysis on AMR funding
- Presentation of AMR funding schemes by countries

#### Questions for the presentations:

- Which are the common denominators of funding schemes
- Areas for coordination/collaboration: gap analysis
- Opportunities for global funding initiatives: Which is the type of research that needs to be funded at global level?

|     |       | Funding AMR research: the British   | Speaker:  |
|-----|-------|---|---|
| 15' | 14:00 | approach  | John Savill, Chief Executive of the<br>Medical Research Council, UK |
| 45' | 14:15 | <ul> <li>Dennis M. Dixon, Chief, Bacteriology and Mycology Branch, National Institute of Allergy and Infectious Diseases, NIH, USA</li> <li>Niresh Bhagwandin, Executive Manager: Strategic Research Initiatives, South African Medical Research Council</li> <li>A representative from the World Bank (tbc)</li> </ul> |   |
| 30' | 15:00 | Debate: gaps and needs  | Debate: relationship with public funding                            |

#### 30' **COFFEE BREAK**

# Session 2: Implementing the SRA: opportunities for global funding

Moderator: Marc Oullette, Director, Canadian Institutes of Health Research, Canada

#### Scope:

 Presentation of AMR funding schemes by countries/agencies by SRA topics that needs a global action

# Questions for the presentations:

- Which are the common denominators of funding schemes
- Areas for coordination/collaboration: gap analysis
- Opportunities for global funding initiatives: Which is the type of research that needs to be funded at global level?

| 60' | 16:00          | <ul> <li>Warwick Anderson, Chief Executive Officer, National Health &amp; Medical Research Council, Australia (recorded)</li> <li>Jayaraman Gowrishankar, Centre for DNA Fingerprinting and Diagnostics, Department of Biotechnology, Ministry of Science and Technology, Govt of India</li> <li>Marcelo Gala, Director, National Institute for Infectious Diseases, Argentina</li> <li>Ruxandra DRAGHIA-AKLI, Director General DG Health, European Commission</li> </ul> |
|-----|----------------|---|
| 30' | 17:30<br>18:00 | Open discussion and concluding remarks: presentation of Statement on AMR  Cocktail reception  |